Targeting Integrin β3 in Endothelial Cells Attenuates Cardiac Fibrosis Through the Calcium-Calmodulin-Dependent Protein Kinase IIα- cAMP-Responsive Element Binding Protein 1 Signaling Axis in Pressure Overload-Induced Heart Failure

J Am Heart Assoc. 2026 Apr 22:e046276. doi: 10.1161/JAHA.125.046276. Online ahead of print.ABSTRACTBACKGROUND: Endothelial-to-mesenchymal transition (EndMT) is a key contributor to cardiac fibrosis, yet the role and underlying mechanisms of endothelial integrin β3 (ITGB3) activation in EndMT remain

M Mengwen Wang

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography (GOLDMINE): A Multi-Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes

Aliment Pharmacol Ther. 2026 Apr 22. doi: 10.1111/apt.70696. Online ahead of print.ABSTRACTBACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) exhibits marked heterogeneity in fibrosis progression and liver-related outcomes. Liver biopsy is not feasible for longitudinal risk

S Suzanne Sharpton

How to Image Myocarditis

Circ Cardiovasc Imaging. 2026 Apr 22:e018547. doi: 10.1161/CIRCIMAGING.125.018547. Online ahead of print.ABSTRACTMyocarditis is an inflammatory disease involving the heart muscle and potentially the pericardium. While there are many potential causative agents, commonly grouped into infectious (viral

J Jan Gröschel

In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance

J Antimicrob Chemother. 2026 Apr 3;81(5):dkag136. doi: 10.1093/jac/dkag136.ABSTRACTOBJECTIVES: Effective alternatives to standard of care treatment for E. faecalis infective endocarditis (EFIE) are needed. Some in vitro studies have suggested daptomycin and ceftaroline have synergistic activity agai

M María-Alexandra Cañas

Cardiovascular Events and Management Strategies Including Tyrosine Kinase Inhibitor Switching, Dose Reduction, and Discontinuation in Chronic Myeloid Leukemia: A Single-Center Retrospective Study

Cureus. 2026 Mar 21;18(3):e105578. doi: 10.7759/cureus.105578. eCollection 2026 Mar.ABSTRACTThe development of tyrosine kinase inhibitors (TKIs) has dramatically improved the treatment outcomes of the chronic myelogenous leukemia-chronic phase (CML-CP). However, cardiovascular events (CVEs), such as

N Nobue Sato